RA0269

antibody from Oursmab

Targeting: GCGR GGR

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0269

Provider

Oursmab

Product name

Crotedumab (Biosimilar Reference Antibody) (GCGR)

Antibody type

Monoclonal

Description

Crotedumab (REGN1193) is an investigational humanized IgG4 monoclonal antibody developed as a glucagon receptor antagonist. It is designed to specifically bind to and inhibit the activity of the glucagon receptor, a key regulator of glucose metabolism. This mechanism of action positions it as a potential novel therapy for metabolic disorders, most notably type 2 diabetes mellitus, where excessive glucagon signaling contributes to hyperglycemia. By modulating this pathway, it aims to lower blood glucose levels through a mechanism distinct from current insulin-centric or incretin-based therapies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.